StreetAlpha.app
Home › Stocks › IGC

IGC Pharma, Inc. (IGC)

$0.17
▼ −8.70%
LAST CLOSE · NOV 20

IGC Pharma develops drug candidates for Alzheimer's disease, with its lead candidate in clinical trials for agitation linked to the condition. It last closed at $0.17 on Nov 20, down 8.70% on the day. For the quarter ended Sep 2026, IGC reported EPS of -$0.02 on revenue of $328,000, with revenue up 71.7% from a year ago.

AI Auto Pilots
Is IGC in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold IGC.

Key Stats

Last 12 months
Results
Revenue
$1.3M
+13.9% vs a year ago
Net income
−$8.1M
−643.7% margin
EPS (diluted)
−$0.08
Free cash flow
−$5.2M
−415.2% margin
Valuation
Market cap
$19.6M
116.7M shares
P/E
–
No P/E while losing money
Price to sales
15.6
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$377K
At Sep 30
Debt
$128K
At Sep 30
Shareholder equity
$6.5M
Shares outstanding
116.7M
At Nov 3
Fiscal year endsDecember
ExchangeNYSE
Financials history
FY2021: $898K$898KFY2021FY2022: $397K$397KFY2022FY2023: $911K$911KFY2023FY2024: $1.3M$1.3MFY2024FY2025: $1.3M$1.3MFY2025

From IGC's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 6). Last 12 months adds up the four latest quarters.

Next report
—
No date on file yet
Reported EPS
-$0.02
Quarter ended Sep 2026
Year ago EPS
-$0.02
Same quarter last year
Revenue
$328,000
+71.7% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.02Dec '24Mar 2025: -$0.02Mar '25Jun 2025: -$0.02Jun '25Sep 2025: -$0.02Sep '25Dec 2025: -$0.01Dec '25Mar 2026: -$0.02Mar '26Jun 2026: -$0.03Jun '26Sep 2026: -$0.02Sep '26Latest -$0.02
Revenue by quarter
Dec 2024: $257,000Dec '24Mar 2025: $330,000Mar '25Jun 2025: $328,000Jun '25Sep 2025: $191,000Sep '25Dec 2025: $350,000Dec '25Mar 2026: $317,000Mar '26Jun 2026: $265,000Jun '26Sep 2026: $328,000Sep '26Latest $328,000
StreetAlpha's call on IGCStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on IGC
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on IGC

Technical Analysis

IGC · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 18% below its 20 day and 43% below its 50 day average. It is 62% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 32), near oversold. The nearest support is the Pivot S1 at $0.16, and the nearest resistance the Pivot at $0.17.

Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityHigh, 10.7%/day
Key levels
$0.3652 week high+111.8%
$0.27200 day average+58.8%
$0.26100 day average+52.9%
$0.2450 day average+41.2%
$0.21Swing high (Nov 9)+23.5%
$0.2020 day average+17.6%
$0.18Pivot R1+5.9%
$0.17Pivot+0.0%
$0.17Last close
$0.16Pivot S1−5.9%
$0.0852 week low−52.9%
$0.08Swing low (Oct 29)−52.9%
Indicators
RSI (14)32.14Weak, oversold below 30Neutral
MACD-0.02Below its signal lineBearish
Stochastic37.2Middle of its rangeNeutral
ADX (14)60.0Strong downtrend
Williams %R-100.0Oversold below −80, overbought above −20Oversold
CCI (20)-98.5Oversold below −100, overbought above 100Neutral
Rate of change−16.0%Change over 10 sessionsBearish
ATR (14)$0.02Typical daily range, 10.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for IGC

What happened before

See how IGC did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow IGC usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How IGC has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for IGCHow many large options trades hit IGC, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

IGC Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▼11 buying vs 15 selling
  • ▲Held by funds +0.9 pts
  • ▼Funds holding -7
  • ▲Superinvestors: 2 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding2936−19.4%
In funds' top 1000–
Held by funds5.4%4.5%+0.9 pts
New / increased2 / 96 / 7−15.4%
Reduced / sold out6 / 97 / 4+36.4%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See IGC institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IGC is in one of them and how their past IGC trades turned out.

IGC in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered IGC in an article yet. Here's the latest on the wider market.

About IGC Pharma

IGC Pharma is a drug development company based in Potomac, Maryland, focused mainly on Alzheimer's disease. Its lead candidate, IGC-AD1, is in a clinical trial for agitation, a behavioral symptom common in people with Alzheimer's dementia. The company is also building MINT-AD, an artificial intelligence data tool meant to support clinicians and researchers in assessing risk in Alzheimer's patients. It does not yet sell pharmaceutical products.

Headquarters
Potomac, MD